drugset / Trial / NCT05007145
PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Subjects With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
Phase 2
Unknown
92 enrolled
Fujian Cancer Hospital
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to explore the efficacy and safety of compare the efficacy and safety of PD-1 inhibitor and chemotherapy（treatment group） with chemoradiotherapy（control group） in neoadjuvant treatment of resectable thoracic esophageal squamous cell carcinoma.
Timeline
- Start
- 2021-08-15
- Primary completion
- 2023-08-31
- Completion
- 2023-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Albumin-Bound Paclitaxel | Unknown | 125 mg/m2 | — |
| Background | Cisplatin | Other / unclassified | 75 mg/m2 | — |